NRS
TEVA icon

Neville Rodie & Shaw’s Teva Pharmaceuticals TEVA Stock Holding History

Neville Rodie & Shaw’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-10,100
Closed -$382K – 265
2013
Q3 		$382K Sell
10,100
-125
-1% -$4.88K 0.04% 178
2013
Q2 		$400K Buy
+10,225
New +$398K 0.05% 170

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Neville Rodie & Shaw's TEVA Position: Q4 2013 in Review

Neville Rodie & Shaw sold out of Teva Pharmaceuticals (TEVA) in Q4 2013, closing a stake of 10,100 shares — an estimated $382K sold.

Neville Rodie & Shaw first reported a position in TEVA in Q2 2013 and held it in 2 quarters. The position peaked at $400K in Q2 2013. 727 funds tracked by Wall St. Rank hold TEVA as of Q4 2013.

  • Neville Rodie & Shaw reported no remaining Teva Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Neville Rodie & Shaw sold 10,100 Teva Pharmaceuticals shares in Q4 2013, an estimated $382K.
  • Neville Rodie & Shaw first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Neville Rodie & Shaw's Teva Pharmaceuticals position peaked at $400K in Q2 2013.
  • 727 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2013.

Based on Neville Rodie & Shaw's 13F filing for Q4 2013, filed 13 Jan 2014.